Federated Hermes’s Harvard Bioscience HBIO Stock Holding History

Federated Hermes’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-73	Closed	-$356	–	2099
2026 Q1	$356	Sell	73 -93	-56%	-$520	﹤0.01%	2035
2025 Q4	$1.11K	Hold	166	–	–	﹤0.01%	2013
2025 Q3	$726	Hold	166	–	–	﹤0.01%	2088
2025 Q2	$735	Hold	166	–	–	﹤0.01%	2018
2025 Q1	$937	Buy	+166	New	+$2.13K	﹤0.01%	2002
2022 Q1	–	Sell	-85	Closed	-$6K	–	2240
2021 Q4	$6K	Hold	85	–	–	﹤0.01%	1979
2021 Q3	$6K	Hold	85	–	–	﹤0.01%	2027
2021 Q2	$7K	Buy	85 +25	+42%	+$1.77K	﹤0.01%	2009
2021 Q1	$3K	Buy	+60	New	+$2.92K	﹤0.01%	2093
2015 Q2	–	Sell	-35	Closed	-$2K	–	1999
2015 Q1	$2K	Sell	35 -147	-81%	-$7.9K	﹤0.01%	1941
2014 Q4	$10K	Buy	182 +12	+7%	+$572	﹤0.01%	1745
2014 Q3	$7K	Buy	+170	New	+$7.82K	﹤0.01%	1782

Other funds holding HBIO

WCM

Weber Capital Management San Francisco, California $118M AUM

MIM

Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

CCM

Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes's HBIO Position: Q2 2026 in Review

Federated Hermes sold out of Harvard Bioscience (HBIO) in Q2 2026, closing a stake of 73 shares — an estimated $356 sold.

Federated Hermes first reported a position in HBIO in Q3 2014 and held it in 12 quarters. The position peaked at $10K in Q4 2014. 37 funds tracked by Wall St. Rank hold HBIO as of Q2 2026.

Federated Hermes reported no remaining Harvard Bioscience position as of Q2 2026 after selling out during the quarter.
Federated Hermes sold 73 Harvard Bioscience shares in Q2 2026, an estimated $356.
Federated Hermes first reported a position in Harvard Bioscience in Q3 2014 and held it in 12 quarters.
Federated Hermes's Harvard Bioscience position peaked at $10K in Q4 2014.
37 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.